High post-void residual volume predicts worse durability after prostatic artery embolization

Baseline PVR ≥300 mL triples risk of PAE failure: composite endpoint (prostate surgery or indwelling catheter) 38.7% vs 11.3% (RR 3.43; 95% CI 1.76–6.70; p=0.0003) in this retrospective cohort. Early symptom scores improved similarly regardless of PVR, but durability suffers.

• Single-center retrospective study; 176 of 573 PAE procedures met inclusion criteria (PVR ≥300 mL: n=25 vs <300 mL: n=151); inverse probability of treatment weighting used to adjust for confounding.
• IPSS and QoL improvements at 3–6 and 12 months were comparable between groups, suggesting PAE provides short-term symptom relief even in high-PVR patients but does not prevent late failure.
• Key limitation: small high-PVR subgroup (n=25) at a single center limits statistical precision and generalizability; findings require prospective, multi-center validation before changing patient selection criteria.

RadPigeon summaries are original and for information only. They are not clinical advice.